G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial-Reference-Cited by-同舟云学术

G-CSF plus azacitidine versus azacitidine alone for patients with high-risk myelodysplastic syndrome: academic, open label, randomized trial

Published:2022-07-07 Issue:7 Volume:12 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Stopka Tomáš^ORCID,Minařík Lubomír^ORCID,Dusilková Nina,Pešta Michal,Kulvait Vojtěch^ORCID,Špaček Martin,Zemanová Zuzana,Kalousová Marta,Jonášová Anna^ORCID

Abstract

Trial registration GA trial is registered under EudraCT#: 2013-001639-38.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

https://www.nature.com/articles/s41408-022-00698-2.pdf

Reference15 articles.

1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

2. Fenaux P, Gattermann N, Seymour JF, Hellstrom-Lindberg E, Mufti GJ, Duehrsen U, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol. 2010;149:244–9.

3. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–32.

4. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28:562–9.

5. Garcia JS, Wei AH, Borate U, Fong CY, Baer MR, Nolte F, et al. Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. Abstract #656 Presented at the 2020 ASH Annual Meeting 2020.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes;Seminars in Hematology;2024-08

2. Filgrastim Used for Infection Prophylaxis for Moderate Neutropenia Related to Primary Myelodysplasia Prior to Elective Surgery: A Case Report;EMJ Hematology;2024-07-25

3. Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review;Journal of Oncology Pharmacy Practice;2024-03-21

4. Attenuated cell cycle and DNA damage response transcriptome signatures and overrepresented cell adhesion processes imply accelerated progression in patients with lower‐risk myelodysplastic neoplasms;International Journal of Cancer;2024-01-05

5. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex;British Journal of Cancer;2022-12-08